Study Details
A study to compare the efficacy and safety of Tacrolimus capsules and Cyclophosphamide injection in treatment of lupus nephritis
Clinicaltrials.gov ID
Astellas Study ID
F506-CL-0912
EudraCT ID
N/A
Condition
Lupus
Phase
Phase 3
Age
18 years - 60 years
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Mar 2015 - Sep 2018
Masking
None (Open Label)
Enrollment number
314
A phase III, randomized, open, parallel-controlled, multi-center study to compare the efficacy and safety of Tacrolimus capsules and Cyclophosphamide injection in treatment of lupus nephritis
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A study to compare the efficacy and safety of Tacrolimus capsules and Cyclophosphamide injection in treatment of lupus nephritis? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site CN00020
Shijiazhuang, China
Site CN00041
Xiamen, China
Site CN00034
Beijing, China
Site CN00026
Changchun, China
Site CN00025
Nanjing, China
Site CN00047
Shijiazhuang, China
Site CN00017
Shenzhen, China
Site CN00014
Shanghai, China
Site CN00043
Hefei, China
Site CN00002
Chengdu, China
Site CN00027
Changsha, China
Site CN00030
Beijing, China
Site CN00001
Shanghai, China
Site CN00048
Lishui, China
Site CN00045
Liuzhou, China
Site CN00037
Nanning, China
Site CN00056
Guangzhou, China
Site CN00044
Wulumuqi, China
Site CN00010
Hangzhou, China
Site CN00019
Shenyang, China
Site CN00012
Nanjing, China
Site CN00018
Shenyang, China
Site CN00038
Nanning, China
Site CN00053
Tianjin, China
Site CN00023
Wuhan, China
Site CN00028
Zhengzhou, China
Site CN00013
Nanjing, China
Site CN00049
Wuxi, China
Site CN00052
Taiyuan, China
Site CN00032
Qingdao, China
Site CN00021
Tianjin, China
Site CN00024
Wuhan, China
Site CN00042
Changchun, China
Site CN00003
Chengdu, China
Site CN00015
Shanghai, China
Site CN00050
Changsha, China
Site CN00005
Dalian, China